Capecitabine

From OncoWiki
Jump to: navigation, search

Drug information

Xeloda

Indication

Hepatocellular Carcinoma

  • Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days
  • Q3w

References

Patt, YZ et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578


Colon Cancer

Adjuvant chemotherapy

  • Capecitabine (Xeloda) 1250 mg/m2 po bid x 14 days
  • Q3w x 8 cycles

References

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696

Chemotherapy for stage IV (metastatic) cancer

  • Capecitabine (Xeloda) 1000-1250 mg/m2 po bid x 14 days q3w till disease progression

References

Van Cutsem, E et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19:4097

Hoff, PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282

Gastric Cancer

Chemotherapy for locally advanced unresectable and metastatic cancer

  • Capecitabine (Xeloda) 1000 mg/m2 po bid for 2wks
  • Q3w

References

Hong, YS et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15:1344